Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P
Department of Internal Medicine, University of Pavia, Italy.
Transfusion. 1997 Feb;37(2):135-40. doi: 10.1046/j.1537-2995.1997.37297203514.x.
Hypertransfusion with a baseline hemoglobin of 10 to 12 g per dL is still considered by many to be the mainstay of conservative therapy for beta-thalassemia major. However, this regimen is frequently associated with manifestations of transfusion iron overload, despite regular chelation therapy with subcutaneous desferoxamine.
To verify whether a transfusion regimen with a target pretransfusion hemoglobin level between 9 and 10 g per dL can allow a significant reduction in blood consumption, while still effectively suppressing erythropoiesis, the records were reviewed of 32 beta-thalassemia major patients, who were maintained at a pretransfusion hemoglobin of 11.3 +/- 0.5 g per dL between 1981 and 1986. These patients were switched at the beginning of 1987 to a transfusion regimen with pretransfusion hemoglobin of 9.4 +/- 0.4 g per dL. The degree of erythroid marrow activity was evaluated in these patients and in 32 subjects with beta-thalassemia intermedia through the simple measurement of serum transferrin receptor.
After the adoption of the moderate transfusion regimen, transfusion requirements decreased from 137 +/- 26 to 104 +/- 23 mL per kg per year of red cells (p < 0.0001), and mean serum ferritin decreased from 2448 +/- 1515 to 1187 +/- 816 micrograms per L (p < 0.0001), with one-half of patients achieving serum ferritin levels lower than 1000 micrograms per L. The proportion of patients having spontaneous pubertal development increased significantly (p < 0.01), as a result of less iron-related gonadotropin insufficiency. At the lower pretransfusion hemoglobin, erythroid marrow activity did not exceed two to three times normal levels in most subjects.
As compared with hypertransfusion, moderate transfusion may allow more effective prevention of iron loading, with higher likelihood of spontaneous pubertal development and without producing excessive expansion of erythropoiesis.
许多人仍认为,对于重型β地中海贫血,以10至12 g/dL的基线血红蛋白进行强化输血是保守治疗的主要手段。然而,尽管使用皮下去铁胺进行定期螯合治疗,这种治疗方案仍经常与输血性铁过载的表现相关。
为了验证目标输血前血红蛋白水平在9至10 g/dL之间的输血方案是否能显著减少血液消耗量,同时仍能有效抑制红细胞生成,回顾了32例重型β地中海贫血患者的记录,这些患者在1981年至1986年间维持输血前血红蛋白为11.3±0.5 g/dL。这些患者在1987年初改为输血前血红蛋白为9.4±0.4 g/dL的输血方案。通过简单测量血清转铁蛋白受体,评估了这些患者以及32例中间型β地中海贫血患者的红系骨髓活性程度。
采用适度输血方案后,红细胞的输血需求量从每年每千克137±26 mL降至104±23 mL(p<0.0001),平均血清铁蛋白从2448±1515μg/L降至1187±8 μg/L(p<0.0001),一半的患者血清铁蛋白水平低于1000μg/L。由于与铁相关的促性腺激素不足减少,自发青春期发育的患者比例显著增加(p<0.01)。在较低的输血前血红蛋白水平下,大多数受试者的红系骨髓活性未超过正常水平的两到三倍。
与强化输血相比,适度输血可能更有效地预防铁负荷增加,自发青春期发育的可能性更高,且不会导致红细胞生成过度增加。